BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Summary: PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastroph...

Full description

Bibliographic Details
Main Authors: Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V. Kossenkov, Andrew J. Wilson, Fiona Simpkins, David Speicher, Dineo Khabele, Benjamin G. Bitler, Rugang Zhang
Format: Article
Language:English
Published: Elsevier 2017-12-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S221112471731762X

Internet

http://www.sciencedirect.com/science/article/pii/S221112471731762X

Similar Items